Probably the most well-known drug on the domestic market for correcting body weight. Produced by the Russian company Ozon ROS LLC in capsules of 10 and 15 mg, the active ingredient is Sibutramine hydrochloride.

Mechanism of action : central.

It has an effect on the saturation center located in the hypothalamus, one of the parts of the brain.

Under the influence of Reduxin, the action of serotonin and norepinephrine secreted by the nerve endings on specific receptors of the saturation center is prolonged (lengthened).

As a result, a person does not feel hungry for a long time, and consumes less food.

In addition, Reduxin helps to speed up metabolism and the breakdown of adipose tissue. Weight loss is accompanied by an anti-atherosclerotic effect due to a decrease in low and very low density lipoproteins, which are responsible for the formation of atherosclerotic plaques on the walls of blood vessels.

Side effects: mainly associated with the negative effect on the cardiovascular system of norepinephrine and serotonin. This action is expressed in a rapid heartbeat, high blood pressure, a feeling of general discomfort.

Contraindications Key words: hypertension, coronary heart disease, thyroid and adrenal diseases, cerebral stroke.

The drug is not recommended for the treatment of psychogenic obesity (so-called bulimia nervosa) and obesity due to thyroid hormone deficiency. The combination with drugs from the group of antihypertensives, hypnotics, neuroleptics and tranquilizers is contraindicated.

Tradename: Reduxin™

International non-proprietary name: Sibutramine

Chemical Name: N- –3-methylbutyl]-N,N-dimethyl-aminohydrochloride monohydrate

Clinical and pharmacological group

16.006 (Central acting anti-obesity drug)

ATC code: A08AA10

Release form, composition and packaging

Capsules, 10 mg: blue, number 2.

Capsules, 15 mg: blue, number 2.

Capsule contents - powder of white or white color with a slightly yellowish tint.

Active substance: Sibutramine hydrochloride monohydrate 10 mg and 15 mg;
Excipients: microcrystalline cellulose, calcium stearate.
Capsule composition:
- for a dosage of 10 mg: titanium dioxide dye, erythrosin dye, proprietary blue dye, gelatin;
- for a dosage of 15 mg: titanium dioxide dye, proprietary blue dye, gelatin.

pharmachologic effect

Combined drug for the treatment of obesity, the action of which is due to its constituent components.

Sibutramine is a prodrug and exerts its effect in vivo through metabolites (primary and secondary amines) that inhibit the reuptake of monoamines (mainly serotonin and norepinephrine).

An increase in the content of neurotransmitters in synapses increases the activity of central serotonin 5-HT receptors and adrenoreceptors. This contributes to an increase in the feeling of satiety and a decrease in the need for food, as well as an increase in thermal production.

Indirectly activating β3-adrenergic receptors, sibutramine acts on brown adipose tissue. Weight loss is accompanied by an increase in the concentration of HDL in the blood serum and a decrease in the amount of triglycerides, total cholesterol, LDL, and uric acid.

Sibutramine and its metabolites do not affect the release of monoamines, do not inhibit MAO; do not have affinity for a large number of neurotransmitter receptors, including serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), adrenoreceptors (β1, β2, β3, α1, α2), dopamine (D1, D2), muscarinic, histamine (H1), benzodiazepine and NMDA receptors.

Microcrystalline cellulose is an enterosorbent, has sorption properties and a nonspecific detoxification effect. It binds and removes from the body various microorganisms, their metabolic products, toxins of exogenous and endogenous nature, allergens, xenobiotics, as well as an excess of some metabolic products and metabolites responsible for the development of endogenous toxicosis.

Pharmacokinetics

Absorption, distribution, metabolism

After taking the drug inside, sibutramine is rapidly absorbed from the gastrointestinal tract, not less than 77%. It undergoes the effect of “first passage” through the liver and is biotransformed with the participation of the 3A4 isoenzyme of cytochrome P450 with the formation of two active metabolites (mono- and didesmethylsibutramine).

After taking a single dose of 15 mg Cmax monodesmethylsibutramine is 4 ng / ml (3.2-4.8 ng / ml), didesmethylsibutramine - 6.4 ng / ml (5.6-7.2 ng / ml). C max sibutramine is achieved after 1.2 hours, active metabolites - after 3-4 hours.

Reception simultaneously with food reduces the Cmax of metabolites by 30% and increases the time to reach it by 3 hours without changing the AUC. Rapidly distributed into tissues.

The binding of sibutramine to plasma proteins is 97%, and that of mono- and didesmethylsibutramine is 94%. C ss of active metabolites in the blood is achieved within 4 days after the start of treatment and is approximately 2 times higher than the plasma level after taking a single dose.

breeding

T 1/2 sibutramine - 1.1 h, monodesmethylsibutramine - 14 h, didesmethylsibutramine - 16 h. Active metabolites undergo hydroxylation and conjugation to form inactive metabolites, which are excreted mainly by the kidneys.

Dosage

Reduxin is prescribed orally 1 time / day. The dose is set individually, depending on tolerability and clinical efficacy.

Capsules should be taken in the morning without chewing and drinking plenty of liquid. The drug can be taken on an empty stomach or combined with food intake.

If a weight loss of 5% or more is not achieved within 4 weeks from the start of treatment, then the dose is increased to 15 mg / day.

The duration of therapy with Reduxin should not exceed 3 months in patients who do not respond well enough to therapy (i.e., who fail to reduce weight by 5% of the initial body weight within 3 months of treatment).

Treatment should not be continued if, with further therapy (after achieved weight loss), the patient again gains 3 kg or more in body weight.

The total duration of therapy should not exceed 2 years, since there are no data on efficacy and safety for a longer period of taking sibutramine.

Therapy with Reduxin should be carried out by a doctor with practical experience in the treatment of obesity. The drug should be combined with diet and exercise.

Overdose

There are extremely limited data on overdose of sibutramine. In case of overdose, the patient should consult a doctor.

Symptoms: may increase the severity of side effects. Specific signs of overdose are unknown.

Treatment: taking activated charcoal, gastric lavage, symptomatic therapy, with an increase in blood pressure and tachycardia - the appointment of beta-blockers. There is no specific treatment or specific antidotes.

It is necessary to perform general measures: ensure free breathing, monitor the state of the cardiovascular system, and, if necessary, carry out supportive symptomatic therapy. The effectiveness of forced diuresis or hemodialysis has not been established.

drug interaction

Inhibitors of microsomal oxidation, incl. inhibitors of cytochrome P450 isoenzyme 3A4 (including ketoconazole, erythromycin, cyclosporine) increase plasma concentrations of sibutramine metabolites with an increase in heart rate and a clinically insignificant increase in the QT interval. Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, phenobarbital and dexamethasone can accelerate the metabolism of sibutramine.

The simultaneous use of several drugs that increase the content of serotonin in the blood can lead to the development of a serious interaction.

The so-called serotonin syndrome can develop in rare cases with the simultaneous use of Reduxin with selective serotonin reuptake inhibitors (drugs for the treatment of depression), with some drugs for the treatment of migraine (sumatriptan, dihydroergotamine), with potent analgesics (pentazocine, pethidine, fentanyl) or antitussives. drugs (dextromethorphan). Sibutramine does not affect the effect of oral contraceptives.

With the simultaneous administration of sibutramine and ethanol, there was no increase in the negative effect of ethanol. However, the use of alcohol is absolutely not combined with the dietary measures recommended when taking sibutramine.

Pregnancy and lactation

The drug should not be used during pregnancy due to the lack of a sufficiently convincing number of studies on the safety of the effects of sibutramine on the fetus.

Women of childbearing age during the reception should use contraceptives.

Reduxin should not be used during breastfeeding.

Side effects

Side effects, depending on the impact on organs and organ systems, are presented in the following order (often -> 10%, sometimes - 1-10%, rarely -< 1%).

From the side of the central nervous system and peripheral nervous system: often - dry mouth, insomnia; sometimes - headache, dizziness, anxiety, paresthesia, and changes in taste; in isolated cases - back pain, depression, drowsiness, emotional lability, anxiety, irritability, nervousness, convulsions.

One patient with schizoaffective disorder thought to have existed prior to treatment developed acute psychosis after treatment.

From the side of the cardiovascular system: sometimes - tachycardia, palpitations, increased blood pressure, vasodilation. There is a moderate rise in blood pressure at rest by 1-3 mm Hg. and a moderate increase in heart rate of 3-7 beats per minute.

In some cases, more pronounced increases in blood pressure and heart rate are not excluded. Clinically significant changes in the level of blood pressure and pulse are recorded mainly at the beginning of treatment (in the first 4-8 weeks).

From the digestive system: often - loss of appetite, constipation; sometimes - nausea, exacerbation of hemorrhoids. With a tendency to constipation in the early days, it is necessary to control the evacuation function of the intestine. If constipation occurs, stop taking and take a laxative. In isolated cases, abdominal pain, a paradoxical increase in appetite, a transient increase in liver enzymes.

Dermatological reactions: sometimes - sweating; in isolated cases - skin itching, Shenlein-Genoch purpura (hemorrhages in the skin).

From the body as a whole: in isolated cases, the following clinically significant adverse events are described: dysmenorrhea, edema, flu-like syndrome, thirst, rhinitis, acute interstitial nephritis, bleeding, thrombocytopenia.

Withdrawal reactions such as headache or increased appetite are rare. There is no evidence that after treatment there is an abstinence syndrome, withdrawal syndrome or mood disorders.

Most often, side effects occur at the beginning of treatment (in the first 4 weeks). Their severity and frequency weaken over time. Side effects are generally mild and reversible.

Terms and conditions of storage

The drug should be stored in a dry place, out of the reach of children, at a temperature not exceeding 25°C. Shelf life - 3 years.

Indications

For weight loss in the following conditions:

Alimentary obesity with a body mass index (BMI) of 30 kg/m2 or more;

Alimentary obesity with a BMI of 27 kg / m 2 or more in combination with other risk factors due to overweight (type 2 diabetes mellitus / non-insulin-dependent / or dyslipoproteinemia).

Contraindications

  • - the presence of organic causes of obesity (hypothyroidism);
  • - serious eating disorders (anorexia nervosa or bulimia nervosa);
  • - mental illness;
  • - Gilles de la Tourette syndrome (generalized tics);
  • - simultaneous use of MAO inhibitors (phentermine, fenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or their use within 2 weeks before the appointment of the drug Reduxin; the use of other drugs acting on the central nervous system (antidepressants, neuroleptics); drugs prescribed for sleep disorders containing tryptophan, as well as other centrally acting drugs for weight loss;
  • - ischemic heart disease, decompensated chronic heart failure, congenital heart disease, peripheral arterial occlusive disease, tachycardia, arrhythmia, cerebrovascular disease (stroke, transient cerebrovascular accident);
  • - uncontrolled arterial hypertension (BP above 145/90 mm Hg);
  • - thyrotoxicosis;
  • - severe liver dysfunction;
  • - severe renal dysfunction;
  • - benign prostatic hyperplasia;
  • - pheochromocytoma;
  • - angle-closure glaucoma;
  • - Established drug, drug or alcohol addiction;
  • - pregnancy;
  • - lactation (breastfeeding);
  • - children and adolescents up to 18 years;
  • - old age over 65 years;
  • - Established hypersensitivity to sibutramine or to other components of the drug.

WITH caution the drug should be prescribed under the following conditions: arrhythmias in history, chronic circulatory failure, coronary artery disease (including history), cholelithiasis, arterial hypertension (controlled and in history), neurological disorders, including mental retardation and convulsions (in including a history), impaired liver and / or kidney function of mild to moderate severity, motor and verbal tics in history.

special instructions

Reduxin should be used only in cases where all non-drug measures to reduce body weight are ineffective - if the weight loss for 3 months was less than 5 kg.

Treatment with the drug should be carried out as part of complex therapy for weight loss under the supervision of a physician with practical experience in the treatment of obesity.

Comprehensive therapy for obesity includes both diet and lifestyle changes and increased physical activity. An important component of therapy is the creation of prerequisites for a stable change in dietary habits and lifestyle, which are necessary to maintain the achieved weight loss even after discontinuation of drug therapy.

As part of Reduxin therapy, patients need to change their lifestyle and habits in such a way that, after completion of treatment, the achieved weight loss is maintained. Patients should clearly understand that failure to comply with these requirements will lead to a repeated increase in body weight and repeated visits to the attending physician.

In patients taking Reduxin, it is necessary to measure blood pressure and heart rate. In the first 2 months of treatment, these parameters should be monitored every 2 weeks, and then monthly.

In patients with arterial hypertension (who have blood pressure levels above 145/90 mm Hg during antihypertensive therapy), this control should be carried out especially carefully and, if necessary, at shorter intervals. In patients in whom blood pressure twice exceeded the level of 145/90 mm Hg during repeated measurement. treatment with Reduxin should be suspended.

Particular attention should be paid to the simultaneous administration of drugs that increase the QT interval. These drugs include blockers of histamine H 1 receptors (astemizole, terfenadine);

antiarrhythmic drugs that increase the QT interval (amiodarone, quinidine, flecainide, mexiletine, propafenone, sotalol);

Gastrointestinal motility stimulants (cisapride, pimozide, sertindole and tricyclic antidepressants). Caution should be observed when using the drug against the background of conditions that are risk factors for an increase in the QT interval (hypokalemia, hypomagnesemia).

The interval between taking MAO inhibitors and Reduxin should be at least 2 weeks.

The relationship between taking the drug and the development of primary pulmonary hypertension has not been established, however, given the well-known risk of drugs in this group, with regular medical monitoring, special attention should be paid to symptoms such as progressive dyspnea (breathing disorder), chest pain and swelling in the legs.

Influence on the ability to drive vehicles and control mechanisms

Taking the drug may limit the patient's ability to drive vehicles and control mechanisms.

In case of impaired renal function

Contraindicated in severe renal impairment. WITH caution the drug should be prescribed for impaired renal function of mild to moderate severity.

In violation of liver function

Contraindicated in severe hepatic impairment. WITH caution the drug should be prescribed for mild to moderate liver dysfunction.

Terms of dispensing from pharmacies

Reduxin is a combination drug for weight loss, in a complex effect it reduces appetite, enhances the feeling of satiety and thermogenesis, and helps to break down body fat.

The active substance of the drug - sibutramine hydrochloride monohydrate - effectively helps to increase the decrease in a person's need for food, and also enhances "heat production", which contributes to the breakdown of fats and the use of incoming calories, and not their deposition. Secondarily activating β3-adrenergic receptors, the active substance also affects heavy brown fats. Weight loss is accompanied by an increase in the concentration of HDL in the blood and a decrease in the content of triglycerides, cholesterol, LDL and uric acid.

The second active component of Reduxin is microcrystalline cellulose - it is she who is responsible for creating a feeling of fullness, a full stomach. In the stomach, cellulose swells, absorbing water and toxic substances (as an absorbent), filling the volume of the stomach. Therefore, while taking Reduxin, it is recommended to drink clean water.

The drug is presented in pharmacies in the form of capsules of two different colors - they differ in the level of content of active ingredients. Blue-colored Reduxin contains 10 mg of sibutramine and 158.5 mg of microcrystalline cellulose, and blue-colored Reduxin contains 15 and 153.5 mg, respectively.

It is important that gradual weight loss gives a big positive boost to the body. After all, in the stomach there are receptors that, when filled with food, give a signal to the brain about saturation. Due to the gradual reduction in caloric content and the amount of food consumed, which is inevitable when taking Reduxin, the stomach gradually shrinks in size, adjusting to new portions. Gradually, the “normal” amount of necessary food is also reduced, and a person develops a persistent habit of eating less for all the time. And even after stopping the course of therapy, this effect naturally persists for a long time and can be saved by you to maintain mass at the current level.

It is important to understand that Reduxin should be taken only if the diet and non-drug measures to reduce body fat have not had an effect - weight loss over 3 months was less than 5 kg.

Indications for use

Reduxin is prescribed exclusively for weight loss, in the following cases:

  • Alimentary obesity with a body mass index (BMI) of 30 kg/m2 or more;
  • Alimentary obesity with a BMI of 27 kg/m2 or more in combination with other risk factors caused by overweight - type 2 diabetes mellitus / non-insulin-dependent / or dyslipoproteinemia.

Application instruction Reduksin, dosages

The drug is taken 1 time per day in the morning (before or during breakfast), without chewing and drinking plenty of liquid.

At the beginning of the course of treatment, a dosage of 10 mg, Reduxin blue capsule, should be used. In case of side effects or feeling unwell, the dosage should be reduced to 5 mg over 4 weeks. Then we go back to 10 mg.

The total time of taking Reduxin should not exceed 3 months, in case of insufficient effectiveness of the therapy - that is, if it is not possible to reduce body weight by 5% of the initial value. If during treatment, upon reaching a given body weight, the effect of gradual weight gain begins to be observed, the drug should be stopped.

The total duration of the use of Reduxin should not exceed 1 year, since longer use of the drug has not been studied.

It is important that Reduxin is taken under the supervision of a physician with practical experience in the treatment of obesity. It is more effective to take the medication in conjunction with diet and exercise.

The effect of the drug in elderly patients does not differ from that in other age groups.

If you miss taking Reduxin, do not take a double dosage next time - this may lead to the development of side effects. Just continue further taking the drug according to the previous scheme.

Contraindications and side effects

The main contraindications for treatment with Reduxin:

  • the presence of organic causes of obesity (for example, hormonal disorders);
  • severe eating disorders (anorexia nervosa or bulimia nervosa);
  • mental illness, Gilles de la Tourette syndrome;
  • simultaneous reception of MAO inhibitors or their use within 2 weeks before the appointment of the drug Reduxin;
  • the use of drugs acting on the central nervous system (for example, antidepressants, antipsychotics); drugs prescribed for sleep disorders containing tryptophan, as well as other centrally acting drugs for weight loss;
  • IHD, decompensated CHF, congenital heart defects, occlusive diseases of peripheral arteries;
  • tachycardia, arrhythmias, stroke, transient disorders of cerebral circulation;
  • uncontrolled arterial hypertension (BP above 145/90 mm Hg);
  • thyrotoxicosis;
  • severe violations of the liver or kidneys;
  • benign prostatic hyperplasia;
  • pheochromocytoma;
  • angle-closure glaucoma;
  • established drug, drug or alcohol addiction;
  • pregnancy and breastfeeding;
  • children and adolescents up to 18 years of age;
  • individual sensitivity to the active substance or to other components of Reduxin.

Under the following conditions, the drug should be prescribed only under the supervision of a physician: hypertension, mental retardation and convulsions (including history), motor and verbal tics in history.

Side effects

Since Reduxin binds water in the stomach, some of the most common side effects are dry mouth, lack of appetite, constipation and sleep disturbance.

Additionally, disorders such as dizziness, headache, nausea, anxiety, taste disturbance, increased blood pressure, tachycardia, acute forms of hemorrhoids and increased sweating may be observed.

Reception Reduksin can cause some other side effects:

  • Psychosis, a state with a suicidal direction of thinking and suicide - when such symptoms appear, the drug is immediately stopped;
  • diarrhea and vomiting;
  • Baldness;
  • The appearance of short-term memory impairment and seizures;
  • Violation of urination;
  • Violation of the field of vision;
  • impotence, problems with ejaculation and orgasm;
  • The occurrence of uterine bleeding and menstruation disorders;
  • Various allergic reactions - skin rashes, urticaria, itching, anaphylaxis, Quincke's edema.

Very rarely, a withdrawal reaction can be observed; at the end of the course of taking the drug, it is a headache or increased appetite. There are no data on the identification of withdrawal symptoms or mood disorders.

The most common side effects of Reduxin occur at the initial stage (in the first 4 weeks of treatment). Gradually, their severity decreases, if this does not happen, the possibility of discontinuing or replacing the drug should be considered.

Overdose

Symptoms of an overdose are manifested in an increase in the severity of side effects.

Symptomatic treatment - it is necessary to take absorbents and monitor vital functions, with an increase in blood pressure and heart rate - the appointment of beta-blockers.

It is recommended to follow general measures: unbutton the collar and open the window - ensure free breathing, monitor pressure and pulse. The effectiveness of forced diuresis or hemodialysis has not been clinically established.

Analogues Reduksin, list of drugs

Among the analogues of Reduxin, the following drugs can be distinguished, the list:

  1. Lindax;
  2. Meridia;
  3. Slimia;
  4. Goldline;

It is important to understand that the instructions for use of Reduxin, the price and reviews do not apply to analogues and cannot be used as a guide for the use of drugs of similar composition or action. All therapeutic appointments must be made by a doctor. When replacing Reduxin with an analog, it is important to get expert advice, it may be necessary to change the course of therapy, dosages, etc. Do not self-medicate!

There are three main methods of losing weight: diet, exercise, pills. If an overweight person goes to a doctor and asks him to prescribe a drug for the treatment of obesity, the doctor will prescribe either sibutramine (Redkusin) or orlistat (Xenical). Other medicines are not used in medicine, as they do not have enough evidence of effectiveness and safety.

"Redkusin" is a very controversial drug. On the one hand, it reduces appetite and causes weight loss. On the other hand, its intake is accompanied by a large number of side effects and increases cardiovascular risks.

Diet pills

"Reduxin" is a diet pill. The active substance is sibutramine. Produced by Ozon. There are two dosages - 10 mg and 15 mg.

Indications for use:

  • Obesity (body mass index over 30 kg/m2).
  • Overweight with a body mass index of more than 27 kg / m2, which is combined with type 2 diabetes mellitus or dyslipoproteinemia.

Instructions for use

"Reduxin" at a dose of 15 mg is not prescribed to patients immediately. Starting dosage - 10 mg.

The presence of side effects, poor tolerability of treatment. Then "Reduxin" take 5 mg.

After 4 weeks of treatment, body weight does not decrease, or decreases by less than 5% of the original. Then "Reduxin" is taken at 15 mg per day. This is the maximum allowable daily dose.

After 3 months of treatment, body weight does not decrease, or decreases by less than 5% of the original.

The course of treatment with "Reduxin" is limited. It can continue continuously for no more than 2 years. The reason for this limitation is that there are no research data confirming that the drug is safe for such a long-term use.

Side effects

"Reduxin", especially at a dose of 15 mg, is poorly tolerated by many patients. Despite the fact that the drug is generally safe for health, does not cause irreversible effects, and is only one of two drugs approved for continuous use for more than 1 year, the frequency of side effects is quite high.

"Reduxin" 15 mg most often causes:

  • dry mouth;
  • insomnia;
  • constipation.

The second most common group of side effects (occurs in less than 10% of patients):

  • dizziness;
  • a feeling of crawling all over the body;
  • headache;
  • taste change;
  • anxiety;
  • increased heart rate;
  • increase in blood pressure;
  • nausea;
  • exacerbation of hemorrhoids;
  • sweating.

Other side effects, although their list is quite extensive, it makes no sense to list. They are very rare - less than 1% of patients.

Effect on the heart and blood vessels

"Reduxin" increases cardiovascular risks with long-term use, in particular, increases the risk of ischemic stroke. Therefore, it is contraindicated in patients with certain cardiovascular diseases:

  • cardiac ischemia;
  • occlusive peripheral arterial disease (eg, atherosclerosis);
  • a history of stroke or transient ischemic attacks;
  • tachycardia;
  • heart defects;
  • chronic heart failure in the stage of decompensation;
  • arterial hypertension, which is not stopped by medication.

"Reduxin" 15 mg can only be used in the age group from 18 to 65 years. After this age, there is a significant increase in cardiovascular risks, so the drug may harm elderly patients. In addition, there are not enough studies including patients over 65 years of age.

Due to the increased risk of stroke, sibutramine (the active ingredient in Reduxin) was withdrawn from the pharmaceutical market in a number of countries:

  • Great Britain;
  • China;
  • India;
  • European Union;
  • Canada;
  • Australia;
  • New Zealand;
  • Philippines;
  • Thailand.

Contraindications

In addition to cardiovascular diseases, "Reduxin" 15 mg has other contraindications. Among them:

  • mental disorders: depression, history of mania, bulimia nervosa, anorexia nervosa;
  • hyperthyroidism;
  • pheochromocytoma;
  • some types of glaucoma;
  • urinary retention in prostate pathology;
  • pulmonary hypertension;
  • alcoholism or drug addiction;
  • hypersensitivity to sibutramine;
  • pregnancy.

"Reduxin" is incompatible with drugs from the group of MAO inhibitors, it is undesirable to combine it with other antidepressants. It is forbidden to take any drugs that reduce appetite in parallel.

Reviews of losing weight

There are a large number of reviews on the Internet from patients who took Redkusin, including at a dose of 15 mg. Among them there are both positive and negative comments.

There are very few reports of low efficacy of the drug. Most patients recognize that it has an anorexigenic (appetite-reducing) effect, as they feel it on themselves.

Most of the positive reviews are left by people who managed to lose weight. Most of the negative reviews come from those who have stopped taking Redkusin because of its poor tolerance. The most common complaints are: mood changes (depression or hyperactivity), insomnia, constipation, dry mouth.

Price

"Redkusin" at a dose of 15 mg is available in packs of 30, 60 or 90 capsules. The cheapest way is to take a large package, given that you need to take the drug for a long time.

Doctor's review

Reception of "Reduxin" is justified for obese patients. It will reduce cardiovascular risks rather than increase them. Complications from taking the drug are observed only in isolated cases. At the same time, people get sick and die from obesity very often, because this is one of the main factors that increase the risk of heart and vascular diseases.

But you should be aware of the possible negative impact of "Reduxin" on health, so you need to take it, controlling your condition.

In case of constipation - take laxatives, but not constantly, but only when such a need arises. You can do without them if you increase your fluid and fiber intake.

In the first 4-8 weeks of admission, pulse rate and blood pressure should be monitored. If there is an increase in heart rate of more than 80 beats per minute, and systolic blood pressure above 140 mm Hg, it is worth reducing the dose or canceling the drug.

For most patients who are sufficiently motivated to lose weight, Reduxin helps to reduce weight. But it is worth remembering that this drug does not break down fat. It only depresses the appetite, that is, supplements the diet. Weight loss occurs solely due to a decrease in calorie intake. If, while taking Reduxine, you eat as usual, this will not lead to weight loss.

Active substance

Sibutramine* + [Microcrystalline cellulose](Sibutraminum+ )

ATH:

Pharmacological group

Nosological classification (ICD-10)

Compound

Description of the dosage form

Capsules, 10 mg: blue, number 2.

Capsules, 15 mg: blue, number 2.

Capsule contents- white or white powder with a slightly yellowish tint.

pharmachologic effect

pharmachologic effect- enterosorbent, anorexigenic .

Pharmacodynamics

Reduxin ® is a combined drug, the action of which is due to its constituent components.

Sibutramine is a prodrug and exhibits its effect in vivo due to metabolites (primary and secondary amines) that inhibit the reuptake of monoamines (serotonin, norepinephrine and dopamine). An increase in the content of neurotransmitters in synapses increases the activity of central 5HT-serotonin and adrenergic receptors, which contributes to an increase in satiety and a decrease in the need for food, as well as an increase in thermal production. Indirectly activating beta 3-adrenergic receptors, sibutramine acts on brown adipose tissue. Weight loss is accompanied by an increase in plasma HDL concentration and a decrease in triglycerides, total cholesterol, LDL and uric acid. Sibutramine and its metabolites do not affect the release of monoamines, do not inhibit MAO; have low affinity for a large number of neurotransmitter receptors, including serotonin (5-HT 1, 5-HT 1A, 5-HT 1B, 5-HT 2C), adrenergic (beta 1 -, beta 2 -, beta 3 -, alpha 1 - , alpha 2 -), dopamine (D 1 , D 2), muscarinic, histamine (H 1), benzodiazepine and glutamate (NMDA) receptors.

Cellulose microcrystalline is an enterosorbent, has sorption properties and non-specific detoxification action. It binds and removes from the body various microorganisms, their metabolic products, toxins of exogenous and endogenous nature, allergens, xenobiotics, as well as an excess of some metabolic products and metabolites responsible for the development of endogenous toxicosis.

Pharmacokinetics

After oral administration, it is rapidly absorbed from the gastrointestinal tract by at least 77%. During the initial passage through the liver, it undergoes biotransformation under the influence of the CYP3A4 isoenzyme with the formation of two active metabolites - monodesmethylsibutramine (M1) and didesmethylsibutramine (M2). After taking a single dose of 15 mg Cmax in plasma M1 is 4 ng / ml (3.2-4.8 ng / ml), M2-6.4 ng / ml (5.6-7.2 ng / ml) . C max is achieved after 1.2 hours (sibutramine), 3-4 hours (M1 and M2). Simultaneous food intake lowers Cmax of metabolites by 30% and increases the time to reach it by 3 hours without changing AUC. It is quickly distributed on fabrics. Communication with proteins makes 97% (sibutramine) and 94% (M1 and M2). C ss of active metabolites in plasma is achieved within 4 days after the start of use and is approximately 2 times higher than the concentration in blood plasma after taking a single dose. T 1/2 sibutramine - 1.1 h, M1 - 14 h, M2 - 16 h. Active metabolites undergo hydroxylation and conjugation to form inactive metabolites, which are excreted mainly by the kidneys.

Currently available limited data do not indicate the existence of clinically significant differences in pharmacokinetics in men and women.

Pharmacokinetics in elderly healthy individuals (mean age 70 years) is similar to that in young people.

kidney failure

Renal failure has no effect on the AUC of the active metabolites M1 and M2, except for the M2 metabolite in dialysis patients with end-stage renal disease.

Liver failure

In patients with moderate hepatic insufficiency after a single dose of sibutramine, the AUC of active metabolites M1 and M2 is 24% higher than in healthy individuals.

Indications of the drug

Reduksin ® is indicated for weight loss in the following conditions:

alimentary obesity with a body mass index (BMI) of 30 kg/m 2 or more;

alimentary obesity with a BMI of 27 kg / m 2 or more in combination with type 2 diabetes mellitus and dyslipidemia.

Contraindications

established hypersensitivity to sibutramine or other components of the drug;

the presence of organic causes of obesity (for example, hypothyroidism);

severe eating disorders (anorexia nervosa or bulimia nervosa);

mental illness;

Gilles de la Tourette syndrome (generalized tics);

simultaneous administration of MAO inhibitors (eg phentermine, fenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or their use within 2 weeks before taking the drug Reduxin ® and 2 weeks after the end of its administration; other drugs acting on the central nervous system, inhibiting the reuptake of serotonin (for example, antidepressants), neuroleptics, sleeping pills containing tryptophan, as well as other centrally acting drugs for weight loss or for the treatment of mental disorders;

cardiovascular diseases (in history and at present): ischemic heart disease (myocardial infarction (MI), angina pectoris); chronic heart failure in the stage of decompensation, occlusive diseases of peripheral arteries, tachycardia, arrhythmia, cerebrovascular diseases (stroke, transient disorders of cerebral circulation);

uncontrolled arterial hypertension (BP above 145/90 mm Hg - see also "Special Instructions");

thyrotoxicosis;

severe violations of the liver and / or kidneys;

benign prostatic hyperplasia;

pheochromocytoma;

angle-closure glaucoma;

established pharmacological, drug or alcohol dependence;

pregnancy;

the period of breastfeeding;

age up to 18 years and over 65 years.

Carefully: arrhythmia in history, chronic circulatory failure, coronary artery disease (including history), except for coronary heart disease (MI, angina pectoris); glaucoma, except angle-closure glaucoma, cholelithiasis, arterial hypertension (controlled and history), neurological disorders, including mental retardation and seizures (including history), epilepsy, impaired liver and / or kidney function of mild to moderate severity , motor and verbal tics in history, bleeding tendency, bleeding disorders, taking drugs that affect hemostasis or platelet function.

Use during pregnancy and lactation

Since there are still not enough studies on the safety of sibutramine exposure to the fetus, this drug is contraindicated during pregnancy.

Women of reproductive age should use contraceptives while taking the drug Reduxin ®.

It is contraindicated to take Reduxin ® during breastfeeding.

Side effects

Most often, side effects occur at the beginning of treatment (in the first 4 weeks). Their severity and frequency weaken over time. Side effects are generally mild and reversible. Side effects, depending on the impact on organs and organ systems, are presented in the following order: very often (≥10%); often (≥1%, but<10 %).

From the side of the central nervous system: very often - dry mouth and insomnia; often - headache, dizziness, anxiety, paresthesia, and a change in taste.

From the CCC: often - tachycardia, palpitations, increased blood pressure, vasodilation.

There is a moderate rise in blood pressure at rest by 1-3 mm Hg. Art. and a moderate increase in heart rate by 3-7 bpm. In some cases, more pronounced increases in blood pressure and heart rate are not excluded. Clinically significant changes in blood pressure and pulse are recorded mainly at the beginning of treatment (in the first 4-8 weeks).

The use of the drug Reduxin ® in patients with elevated blood pressure: see "Contraindications" and "Special Instructions".

very often - loss of appetite and constipation, often - nausea and exacerbation of hemorrhoids. With a tendency to constipation in the early days, it is necessary to control the evacuation function of the intestine. If constipation occurs, stop taking and take a laxative.

From the side of the skin: often - increased sweating. In isolated cases, the following clinically significant adverse events have been described during treatment with sibutramine: dysmenorrhea, edema, flu-like syndrome, skin itching, back pain, abdominal pain, paradoxical increase in appetite, thirst, rhinitis, depression, drowsiness, emotional lability, anxiety, irritability, nervousness, acute interstitial nephritis, bleeding, Shenlein-Genoch purpura (bleeding into the skin), convulsions, thrombocytopenia, transient increase in liver enzymes in the blood.

In the course of post-marketing studies, additional adverse reactions have been described, listed below, by organ system:

From the CCC: flickering arrhythmia.

From the immune system: hypersensitivity reactions (from moderate skin rashes and urticaria to angioedema (angioedema) and anaphylaxis).

Mental disorders: psychosis, states of suicidal thinking, suicide and mania. If such conditions occur, the drug must be discontinued.

From the nervous system: convulsions, short-term memory impairment.

From the side of the organ of vision: blurred vision (veil before the eyes).

From the digestive system: diarrhea, vomiting.

From the skin and subcutaneous tissue: alopecia.

From the side of the kidneys and urinary tract: urinary retention.

From the reproductive system: ejaculation / orgasm disorders, impotence, menstrual irregularities, uterine bleeding.

Interaction

Inhibitors of microsomal oxidation, incl. inhibitors of the CYP3A4 isoenzyme (including ketoconazole, erythromycin, cyclosporine), increase plasma concentrations of sibutramine metabolites with an increase in heart rate and a clinically insignificant increase in the QT interval.

Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, phenobarbital and dexamethasone can accelerate the metabolism of sibutramine. The simultaneous use of several drugs that increase the content of serotonin in the blood plasma can lead to the development of a serious interaction. In rare cases, with the simultaneous use of the drug Reduxin ® with SSRIs (drugs for the treatment of depression), some drugs for the treatment of migraine (sumatriptan, dihydroergotamine), potent analgesics (pentazocine, pethidine, fentanyl) or antitussive drugs (dextromethorphan), a so-called. serotonin syndrome.

Sibutramine does not affect the effect of oral contraceptives.

With the simultaneous administration of sibutramine and alcohol, there was no increase in the negative effects of alcohol. However, alcohol is absolutely incompatible with the dietary measures recommended when taking sibutramine.

With simultaneous use with sibutramine of other drugs that affect hemostasis or platelet function, the risk of bleeding increases.

Drug interactions with the simultaneous use of sibutramine with drugs that increase blood pressure and heart rate are currently not fully understood. This group of drugs includes decongestants, antitussives, colds and antiallergic drugs, which include ephedrine or pseudoephedrine. Therefore, in cases of simultaneous administration of these drugs with sibutramine, caution should be exercised. The combined use of sibutramine with drugs for weight loss, acting on the central nervous system, or drugs for the treatment of mental disorders, is contraindicated.

Dosage and administration

inside, 1 time per day, in the morning, without chewing and drinking a sufficient amount of liquid (a glass of water). The drug can be taken on an empty stomach or combined with food intake.

The dose is set individually, depending on tolerability and clinical efficacy. The recommended initial dose is 10 mg, with poor tolerance, 5 mg may be taken. If within 4 weeks from the start of treatment a decrease in body weight of less than 2 kg is achieved, then the dose is increased to 15 mg / day.

Treatment with Reduxin ® should not last more than 3 months in patients who do not respond well enough to therapy, i.e. who within 3 months of treatment fail to achieve a decrease in body weight by 5% of the baseline. Treatment should not be continued if, with further therapy after the achieved weight loss, the patient's body weight increases by 3 kg or more.

The duration of treatment should not exceed 1 year, since there are no data on efficacy and safety for a longer period of taking sibutramine.

Treatment with Reduxin ® should be carried out in combination with diet and exercise under the supervision of a physician with practical experience in the treatment of obesity.

Overdose

Symptoms: There are very limited data on overdose of sibutramine. The most common adverse reactions associated with overdose: tachycardia, increased blood pressure, headache, dizziness. The patient should notify his or her physician in case of suspected overdose. Overdose may increase the severity of side effects.

Treatment: there is no specific treatment or specific antidotes. It is necessary to perform general measures: to ensure free breathing, to monitor the state of the cardiovascular system, and, if necessary, to carry out supportive symptomatic therapy. Timely use of activated charcoal, as well as gastric lavage, can reduce the intake of sibutramine in the body. Patients with high blood pressure and tachycardia - the appointment of beta-blockers. The effectiveness of forced diuresis or hemodialysis has not been established.

special instructions

Reduxin ® should be used only in cases where all non-drug measures to reduce body weight are ineffective - if the weight loss for 3 months was less than 5 kg.

Treatment with Reduxin ® should be carried out as part of complex therapy for weight loss under the supervision of a physician with practical experience in the treatment of obesity.

Comprehensive therapy includes both diet and lifestyle changes and increased physical activity.

An important component of therapy is the creation of prerequisites for a stable change in eating behavior and lifestyle, which are necessary to maintain the achieved weight loss even after discontinuation of drug therapy. As part of Reduxin ® therapy, patients need to change their lifestyle and habits in such a way that, after completion of treatment, the achieved reduction in body weight is maintained.

Patients should clearly understand that failure to comply with these requirements will lead to a repeated increase in body weight and repeated visits to the attending physician.

In patients taking Reduxin ® , it is necessary to measure the level of blood pressure and heart rate. In the first 3 months of treatment, these parameters should be monitored every 2 weeks, and then monthly. If, during two visits in a row, an increase in resting heart rate ≥10 bpm or SBP/dBP ≥10 mm Hg is detected. Art., it is necessary to stop treatment. Patients with arterial hypertension who, during antihypertensive therapy, have a blood pressure level above 145/90 mm Hg. Art., this control should be carried out especially carefully and, if necessary, at shorter intervals. Patients whose blood pressure exceeded the level of 145/90 mm Hg twice during repeated measurement. Art., treatment with Reduxin ® should be canceled (see "Side effects").

In patients with sleep apnea, blood pressure should be carefully monitored.

Particular attention should be paid to the simultaneous administration of drugs that increase the QT interval. These drugs include blockers of histamine H 1 receptors (astemizole, terfenadine); antiarrhythmic drugs that increase the QT interval (amiodarone, quinidine, flecainide, mexiletine, propafenone, sotalol); gastrointestinal motility stimulant cisapride; pimozide, sertindole and tricyclic antidepressants. This also applies to conditions that can lead to an increase in the QT interval (hypokalemia and hypomagnesemia - see "Interaction").

The interval between taking MAO inhibitors (including furazolidone, procarbazine, selegiline) and Reduxin ® should be at least 2 weeks.

Although the relationship between taking the drug Reduxin ® and the development of primary pulmonary hypertension has not been established, however, given the well-known risk for drugs in this group, with regular medical monitoring, special attention should be paid to symptoms such as progressive dyspnea (breathing disorder), chest pain and swelling legs.

If you miss a dose of the drug Reduxin ®, you should not take a double dose of the drug in the next dose, it is recommended to continue further taking the drug according to the prescribed scheme.

The duration of taking the drug Reduxin ® should not exceed 1 year.

When co-administering sibutramine and other serotonin reuptake inhibitors, there is an increased risk of bleeding. In patients predisposed to bleeding, as well as taking drugs that affect hemostasis or platelet function, sibutramine should be used with caution.

Although there are no clinical data on addiction to sibutramine, it should be ascertained whether the patient had a history of drug dependence and pay attention to possible signs of drug abuse.

Influence on the ability to drive vehicles and mechanisms. Taking the drug Reduxin ® may limit the ability to drive vehicles and control mechanisms. During the period of use of the drug Reduxin ®, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Release form

In this article, you can read the instructions for using the drug Reduxin. Reviews of site visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Reduxin in their practice are presented. We kindly ask you to actively add your reviews about the drug: the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Analogues of Reduksin in the presence of existing structural analogues. Use for the treatment of alimentary obesity and weight loss, including during pregnancy and lactation.

Reduxin- a combined drug for the treatment of obesity, the action of which is due to its constituent components. Reduxin (its active substance Sibutramine) is a prodrug and exerts its effect in vivo due to metabolites (primary and secondary amines) that inhibit the reuptake of monoamines (mainly serotonin and norepinephrine). An increase in the content of neurotransmitters in the synapses increases the activity of central serotonin 5-HT receptors and adrenoreceptors, which contributes to an increase in satiety and a decrease in the need for food, as well as an increase in thermal production. Indirectly activating beta3-adrenergic receptors, sibutramine acts on brown adipose tissue. Weight loss is accompanied by an increase in the concentration of HDL in the blood serum and a decrease in the amount of triglycerides, total cholesterol, LDL, and uric acid.

Reduxin and its metabolites do not affect the release of monoamines, do not inhibit MAO; do not have affinity for a large number of neurotransmitter receptors, including serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), adrenoreceptors (beta1, beta2, beta3, alpha1, alpha2), dopamine (D1, D2), muscarinic, histamine (H1), benzodiazepine and NMDA receptors.

Microcrystalline cellulose is an enterosorbent, has sorption properties and a nonspecific detoxification effect. It binds and removes from the body various microorganisms, their metabolic products, toxins of exogenous and endogenous nature, allergens, xenobiotics, as well as an excess of some metabolic products and metabolites responsible for the development of endogenous toxicosis.

Compound

Reduxin consists of two components:

  • sibutramine hydrochloride monohydrate
  • cellulose microcrystalline

Pharmacokinetics

After taking the drug inside, sibutramine is rapidly absorbed from the gastrointestinal tract, not less than 77%. Active metabolites undergo hydroxylation and conjugation to form inactive metabolites, which are excreted primarily by the kidneys.

Indications

For weight loss in the following conditions:

  • alimentary obesity with a body mass index (BMI) of 30 kg/m2 or more;
  • alimentary obesity with a BMI of 27 kg / m2 or more in combination with other risk factors due to overweight (type 2 diabetes mellitus / non-insulin-dependent / or dyslipoproteinemia).

Release form

Dosage form in the form of tablets of the drug Reduxin does not exist. If somewhere you met a mention of pills - do not believe it, this is a fake, which can be dangerous for your health.

Capsules 10 and 15 mg.

Reduxin Light - capsules 625 mg.

Instructions for use

Reduxin is prescribed orally 1 time per day. The dose is set individually, depending on tolerability and clinical efficacy. The recommended initial dose is 10 mg, with poor tolerance, a dose of 5 mg can be taken. Capsules should be taken in the morning without chewing and drinking plenty of liquid. The drug can be taken on an empty stomach or combined with food intake.

If a weight loss of 5% or more is not achieved within 4 weeks from the start of treatment, then the dose is increased to 15 mg per day. The duration of therapy with Reduxin should not exceed 3 months in patients who do not respond well enough to therapy (i.e., who fail to reduce weight by 5% of the initial body weight within 3 months of treatment). Treatment should not be continued if, with further therapy (after achieved weight loss), the patient again gains 3 kg or more in body weight.

The total duration of therapy should not exceed 2 years, since there are no data on efficacy and safety for a longer period of taking sibutramine.

Therapy with Reduxin should be carried out by a doctor with practical experience in the treatment of obesity. The drug should be combined with diet and exercise.

Differences Reduksina Light

Unlike the usual Reduxin Light, the form is a dietary supplement (BAA) and is sold at any pharmacy without a prescription.

Side effect

  • dry mouth, insomnia;
  • headache, dizziness;
  • anxiety;
  • paresthesia;
  • depression;
  • drowsiness;
  • emotional lability, anxiety, irritability, nervousness;
  • convulsions;
  • tachycardia, palpitations;
  • increase in blood pressure;
  • loss of appetite;
  • constipation;
  • nausea;
  • sweating;
  • skin itching;
  • dysmenorrhea;
  • swelling;
  • flu-like syndrome;
  • bleeding;
  • thrombocytopenia.

Most often, side effects occur at the beginning of treatment (in the first 4 weeks). Their severity and frequency weaken over time. Side effects are generally mild and reversible.

Contraindications

  • the presence of organic causes of obesity (for example, hypothyroidism);
  • severe eating disorders (anorexia nervosa or bulimia nervosa);
  • mental illness;
  • Gilles de la Tourette syndrome (generalized tics);
  • simultaneous reception of MAO inhibitors (for example, phentermine, fenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or their use within 2 weeks before the appointment of the drug Reduxin; the use of other drugs acting on the central nervous system (for example, antidepressants, antipsychotics); drugs prescribed for sleep disorders containing tryptophan, as well as other centrally acting drugs for weight loss;
  • coronary artery disease, decompensated chronic heart failure, congenital heart disease, peripheral arterial occlusive disease, tachycardia, arrhythmia, cerebrovascular disease (stroke, transient cerebrovascular accident);
  • uncontrolled arterial hypertension (BP above 145/90 mm Hg);
  • thyrotoxicosis;
  • severe liver dysfunction;
  • severe renal dysfunction;
  • benign prostatic hyperplasia;
  • pheochromocytoma;
  • angle-closure glaucoma;
  • established drug, drug or alcohol addiction;
  • pregnancy;
  • lactation (breastfeeding);
  • children and adolescents up to 18 years of age;
  • old age over 65;
  • established hypersensitivity to sibutramine or to other components of the drug.

Use during pregnancy and lactation

The drug should not be used during pregnancy due to the lack of a sufficiently convincing number of studies on the safety of the effects of sibutramine on the fetus.

Women of childbearing age should use contraceptives while taking Reduxin.

Reduxin should not be used during breastfeeding.

special instructions

Reduxin should be used only in cases where all non-drug measures to reduce body weight are ineffective - if the weight loss for 3 months was less than 5 kg.

Treatment with Reduxin should be carried out as part of complex therapy for weight loss under the supervision of a physician with practical experience in the treatment of obesity.

Comprehensive therapy for obesity includes both diet and lifestyle changes and increased physical activity. An important component of therapy is the creation of prerequisites for a stable change in dietary habits and lifestyle, which are necessary to maintain the achieved weight loss even after discontinuation of drug therapy. As part of Reduxin therapy, patients need to change their lifestyle and habits in such a way that, after completion of treatment, the achieved weight loss is maintained. Patients should clearly understand that failure to comply with these requirements will lead to a repeated increase in body weight and repeated visits to the attending physician.

In patients taking Reduxin, it is necessary to measure blood pressure and heart rate. In the first 2 months of treatment, these parameters should be monitored every 2 weeks, and then monthly. In patients with arterial hypertension (who have blood pressure levels above 145/90 mm Hg during antihypertensive therapy), this control should be carried out especially carefully and, if necessary, at shorter intervals. In patients in whom blood pressure twice exceeded the level of 145/90 mm Hg during repeated measurement. treatment with Reduxin should be suspended.

The interval between taking MAO inhibitors and Reduxin should be at least 2 weeks.

The relationship between taking Reduxin and the development of primary pulmonary hypertension has not been established, however, given the well-known risk of drugs in this group, with regular medical monitoring, special attention should be paid to symptoms such as progressive dyspnea (breathing disorder), chest pain and swelling in the legs.

Influence on the ability to drive vehicles and control mechanisms

Taking the drug Reduxin may limit the patient's ability to drive vehicles and control mechanisms.

drug interaction

Inhibitors of microsomal oxidation, incl. inhibitors of cytochrome P450 isoenzyme 3A4 (including ketoconazole, erythromycin, cyclosporine) increase plasma concentrations of sibutramine metabolites with an increase in heart rate and a clinically insignificant increase in the QT interval. Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, phenobarbital and dexamethasone can accelerate the metabolism of sibutramine. The simultaneous use of several drugs that increase the content of serotonin in the blood can lead to the development of a serious interaction. The so-called serotonin syndrome can develop in rare cases with the simultaneous use of Reduxin with selective serotonin reuptake inhibitors (drugs for the treatment of depression), with some drugs for the treatment of migraine (sumatriptan, dihydroergotamine), with potent analgesics (pentazocine, pethidine, fentanyl) or antitussives. drugs (dextromethorphan). Sibutramine does not affect the effect of oral contraceptives.

With the simultaneous administration of sibutramine and ethanol (alcohol), there was no increase in the negative effect of ethanol. However, the use of alcohol is absolutely not combined with the dietary measures recommended when taking sibutramine.

Analogues of the drug Reduksin

Structural analogues for the active substance:

  • Reduxin Light

In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases that the corresponding drug helps with and see the available analogues for the therapeutic effect.